OncoMatch/Clinical Trials/NCT06929624
A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma
Is NCT06929624 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including SHR-A1912 and Rituximab for diffuse large b-cell lymphoma.
Treatment: SHR-A1912 · Rituximab · Gemcitabine Hydrochloride for · Oxaliplatin — This is a multicenter, randomized, open-label, phase 3 clinical study to evaluate the efficacy of SHR-A1912 combined with R-GemOx in relapsed refractory diffuse large B-cell lymphoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Demographics
Prior therapy
Must have received: systemic antitumor therapy
Have received ≥1 line of systemic antitumor therapy.
Cannot have received: stem cell transplant candidate
Exception: patients who have only one prior line therapy and are candidates for stem cell transplantation
Patients who have only one prior line therapy and are candidates for stem cell transplantation [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06929624 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior stem cell transplant candidate disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify